Pemetrexed Disodium
Pharmacological action:
Pemetrexed enters the cell through the carrier carrying folate and the folate binding protein transport system on the cell membrane. Once pemetrexed enters the cell, it is transformed into the form of polyglutamic acid under the action of folioyl polyglutamic acid synthase. Polyglutamic acid remains in cells and becomes an inhibitor of thymidylate synthase X and glycosamine nucleotide a formyltransferase. Polyglutamic acid showed a time concentration dependent process in tumor cells, but the concentration was very low in normal tissues. The half-life of polyglutamic metabolites in tumor cells is prolonged, which prolongs the action time of drugs in tumor cells.
Matters needing attention:
· This product should be used under the guidance of qualified doctors with anti-tumor drug application experience. This product should be treated in a medical institution with sufficient diagnosis and treatment technology, which can also ensure the timely treatment of complications. The treatment-related adverse reactions seen in clinical studies can be recovered. Patients who were not pretreated with corticosteroids before administration were prone to rash. Dexamethasone (or similar drugs) pretreatment can reduce the incidence and severity of skin reactions.
· It is unclear whether this product causes fluid retention, such as pleural effusion or ascites. For patients with fluid retention with obvious clinical symptoms, it can be considered to drain the body cavity effusion before the use of this product.
· This product is mainly excluded from the body in the form of technical drug through the urinary tract. If the creatinine clearance rate of the patient is 345ml / min, this product does not need dose adjustment. For patients with creatinine clearance < 45ml / min, there is not enough research data to give the recommended dose. Therefore, patients with creatinine clearance rate < 45ml / min should not be treated with this product.
Indication:
This product is used to treat inoperable malignant pleural mesothelioma.
Synonymous： | L-Glutamic Acid Disodium Salt |
CAS： | 150399-23-8 |
Molecular Formula： | C20H19N5Na2O6 |
Molecular Weight： | 471.374 |
Appearance： | White powder |
Storage： | Store at room temperature (10 ~ 30 ℃) in a closed manner, away from light and antifreeze |
Category： | Tumor drugs |
Pemetrexed disodium is a tumor drug successfully developed by Eli Lilly Pemetrexed disodium is a multi-target antifolate preparation with pyrrolidine pyrimidine group in structure. It is a dual inhibitor of nucleotide synthase enzyme / dihydrofolate reductase. It can inhibit cell replication by destroying the normal folate dependent metabolism process in cells, and block three different enzyme targets that are crucial to the survival of cancer cells at the same time, So as to inhibit the growth of tumor.
IUPAC
disodium;(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
SMILES
C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+]
Jiangsu, China
